Chronic hepatitis B (CHB) virus infection is a global public health problem, affecting more
than 400 million people worldwide. The clinical spectrum is wide, ranging from a subclinical …

Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest
rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection …

Background HBeAg seroconversion is an important intermediate outcome in HBeAg-positive
chronic hepatitis B (CHB) patients. This study aimed to compare the effect of nucleos (t) ide …

Mother-to-child transmission (MTCT) of hepatitis B virus (HBV) is a major route of HBV
transmission worldwide despite an existing immunoprophylaxis regimen. The …

Background Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are the two first‐line
anti‐viral therapies for chronic hepatitis B (CHB); however, there are limited studies directly …

The efficacy of entecavir and tenofovir in patients with chronic hepatitis B virus (HBV) is
inconsistent. To address this issue, we conducted a meta‐analysis based on a current …

Little is known about the factors associated with patient compliance with nucleos (t) ide
analog (NUC) treatment for chronic hepatitis B (CHB). The purpose of this study was to …

核苷类抗病毒药物治疗乙肝肝硬化患者的疗效分析 Page 1 2013年第17卷第14期 实用临床医药
杂志 Journal of Ctinical Medicine in Practice ·43· 核苷类抗病毒药物治疗乙肝肝硬化患者的疗效 …

Hepatitis B e antigen (HBeAg) is a soluble viral protein in plasma of patients with hepatitis B
virus infection. HBeAg loss is an important first stage of viral antigen clearance. We …

Abstract Background/Aims Whether the efficacies of entecavir (ETV) and tenofovir disoproxil
fumarate (TDF) in treating liver-related outcomes of decompensated chronic hepatitis B …